Tenax Therapeutics (NASDAQ:TENX) Upgraded to “Strong-Buy” by Leerink Partnrs

Tenax Therapeutics (NASDAQ:TENX) was upgraded by equities researchers at Leerink Partnrs to a “strong-buy” rating in a research report issued on Thursday, Zacks.com reports.

A number of other research analysts also recently issued reports on the stock. StockNews.com began coverage on shares of Tenax Therapeutics in a research report on Thursday, September 26th. They issued a “sell” rating on the stock. William Blair assumed coverage on Tenax Therapeutics in a report on Monday, September 30th. They set an “outperform” rating for the company. Leerink Partners assumed coverage on Tenax Therapeutics in a research note on Thursday. They set an “outperform” rating and a $16.00 target price on the stock. Finally, Guggenheim started coverage on Tenax Therapeutics in a research report on Monday, October 14th. They set a “buy” rating and a $16.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Tenax Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $170.67.

Tenax Therapeutics Price Performance

Shares of TENX stock opened at $4.78 on Thursday. The company’s 50 day moving average is $3.78 and its 200 day moving average is $3.58. Tenax Therapeutics has a 52-week low of $2.77 and a 52-week high of $61.20.

Tenax Therapeutics (NASDAQ:TENX) last released its quarterly earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) EPS for the quarter, topping the consensus estimate of ($1.99) by $0.16. Sell-side analysts expect that Tenax Therapeutics will post -6.75 EPS for the current year.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.